Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.63 |
| ▸ | F10 | P00742 | 4/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932919 | 0.86 | HSD11B1 (0.52) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL13341998 | 0.85 | F2 (0.70) | F2F10SMN1; SMN2KDM4EUSP2 | |
| SCHEMBL20649327 | 0.83 | SIRT1 (0.46) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL19820646 | 0.82 | F2 (0.53) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL28391886 | 0.82 | F2 (0.55) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL28396378 | 0.81 | SIRT1 (0.49) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL20649166 | 0.81 | SIRT1 (0.46) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL3537265 | 0.80 | F10 (0.66) | F2F10SIRT1HSD11B1HSD17B1 | |
| SCHEMBL20355562 | 0.80 | SIRT1 (0.54) | SIRT1SMN1; SMN2KDM4EUSP2ALOX15 | |
| SCHEMBL3538270 | 0.79 | F2 (0.78) | F2F10LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | disclosed |
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | disclosed |
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | disclosed |
| EP-1846381-B1 | HETEROARYLACETAMIDES AS FACTOR Xa INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1846381-B1 | HETEROARYLACETAMIDES AS FACTOR Xa INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-7361672-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361672-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361672-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1846381-A2 | NOVEL HETEROARYLACETAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | US | disclosed |
| WO-2006066778-A2 | NOVEL HETEROARYLACETAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066778-A2 | NOVEL HETEROARYLACETAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | F12, TFPI, F2 | F2 3/4885F10 9/4885SIRT1 1385/4885 |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F2, TFPI, F11 | F2 1/4885F10 24/4885SIRT1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.